Evidence map›Paper›PMID 26424146›Full record

ArticleBMC cancer2015

Aberrant activation of NF-κB signaling in mammary epithelium leads to abnormal growth and ductal carcinoma in situ.

Whitney Barham, Lianyi Chen, Oleg Tikhomirov, Halina Onishko, Linda Gleaves, Thomas P Stricker, Timothy S Blackwell, Fiona E Yull

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Noscapine and Apoptosis in Breast and Other Cancers.International journal of molecular sciences · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Immunity drivesScience advances · 2018
    Article
  15. Article
  16. Oncotarget · 2018
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Whitney BarhamDepartment of Cancer Biology, Vanderbilt University Medical Center, 23rd Ave S and Pierce PRB 325, Nashville, TN, 37232, USA. Whitney.Barham@vanderbilt.edu.
Lianyi ChenDepartment of Cancer Biology, Vanderbilt University Medical Center, 23rd Ave S and Pierce PRB 325, Nashville, TN, 37232, USA. lianyi.chen@vanderbilt.edu.
Oleg TikhomirovDepartment of Cancer Biology, Vanderbilt University Medical Center, 23rd Ave S and Pierce PRB 325, Nashville, TN, 37232, USA. oleg.tikhomirov@vanderbilt.edu.
Halina OnishkoDepartment of Cancer Biology, Vanderbilt University Medical Center, 23rd Ave S and Pierce PRB 325, Nashville, TN, 37232, USA. Hala.Onishko@vanderbilt.edu.
Linda GleavesDepartment of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Ave, Nashville, TN, 37232, USA. Linda.Gleaves@vanderbilt.edu.
Thomas P StrickerDepartment of Pathology, Vanderbilt University Medical Center, 1161 21st Ave, Nashville, TN, 37232, USA. Thomas.Stricker@vanderbilt.edu.
Timothy S BlackwellDepartment of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Ave, Nashville, TN, 37232, USA. Timothy.Blackwell@vanderbilt.edu.
Fiona E YullDepartment of Cancer Biology, Vanderbilt University Medical Center, 23rd Ave S and Pierce PRB 325, Nashville, TN, 37232, USA. Fiona.Yull@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Epithelial NF-KappaB signaling in Mammary TumorigenesisR01CA113734 · NCI · VANDERBILT UNIVERSITY · PI YULL, FIONA E · 2007 to 2011
$1.4M
High-throughput Analysis of Mutations Identified by RNA-sequencing Triple NegativK08CA148912 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STRICKER, THOMAS PAUL · 2012 to 2016
$765k
NCI NIH HHS CA113734NCI NIH HHS K08 CA148912NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NCI NIH HHS R01 CA113734NIDDK NIH HHS DK058404NIDDK NIH HHS P30 DK058404
6 · The paper itself

Abstract

backgroundApproximately 1 in 5 women diagnosed with breast cancer are considered to have in situ disease, most often termed ductal carcinoma in situ (DCIS). Though recognized as a risk factor for the development of more invasive cancer, it remains unclear what factors contribute to DCIS development. It has been shown that inflammation contributes to the progression of a variety of tumor types, and nuclear factor kappa B (NF-κB) is recognized as a master-regulator of inflammatory signaling. However, the contributions of NF-κB signaling to tumor initiation are less well understood. Aberrant up-regulation of NF-κB activity, either systemically or locally within the breast, could occur due to a variety of commonly experienced stimuli such as acute infection, obesity, or psychological stress. In this study, we seek to determine if activation of NF-κB in mammary epithelium could play a role in the formation of hyperplastic ductal lesions.

methodsOur studies utilize a doxycycline-inducible transgenic mouse model in which constitutively active IKKβ is expressed specifically in mammary epithelium. All previously published models of NF-κB modulation in the virgin mammary gland have been constitutive models, with transgene or knock-out present throughout the life and development of the animal. For the first time, we will induce activation at later time points after normal ducts have formed, thus being able to determine if NF-κB activation can promote pre-malignant changes in previously normal mammary epithelium.

resultsWe found that even a short pulse of NF-κB activation could induce profound remodeling of mammary ductal structures. Short-term activation created hyperproliferative, enlarged ducts with filled lumens. Increased expression of inflammatory markers was concurrent with the down-regulation of hormone receptors and markers of epithelial differentiation. Furthermore, the oncoprotein mucin 1, known to be up-regulated in human and mouse DCIS, was over-expressed and mislocalized in the activated ductal tissue.

conclusionsThese results indicate that aberrant NF-κB activation within mammary epithelium can lead to molecular and morphological changes consistent with the earliest stages of breast cancer. Thus, inhibition of NF-κB signaling following acute inflammation or the initial signs of hyperplastic ductal growth could represent an important opportunity for breast cancer prevention.

Indexed as

Signal TransductionAnimalsBiomarkersBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma in SituCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalEnzyme ActivationEpitheliumFemaleGene ExpressionHumansHyperplasiaI-kappa B KinaseBiomarkersI-kappa B KinaseInflammation MediatorsNF-kappa B

Identifiers

PMID26424146
PMCPMC4590702
OpenAlexW2099852924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.